Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.

Brain tumor pathology - 1 Oct 2013

Ohno Makoto, Narita Yoshitaka, Miyakita Yasuji, Matsushita Yuko, Yoshida Akihiko, Fukushima Shintaro, Ichimura Koichi, Shibui Soichiro

Abstract excerpt

Isocitrate dehydrogenase (IDH)1/2 mutations have been proposed as a genetic marker for secondary glioblastoma (sGBM). This study aimed to evaluate the impact of the IDH1/2 mutations on the clinical course and genetic alterations of sGBMs, which histopathologically progressed from lower-grade gliomas. We investigated 18 sGBMs, including 8 sGBMs with IDH1/2 mutations (sGBM-Mut) and 10 with wild-type IDH1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neoplasm Grading

Share to Time Factors

Share to Tumor Suppressor Protein p53

Share to Young Adult

Source

Identifiers

PMID: 23494632
DOI: 10.1007/s10014-013-0140-6

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.PMID 23494632Read ↗

Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.Semantic proximity Read ↗

Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.Semantic proximity Read ↗

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.Semantic proximity Read ↗

The definition of primary and secondary glioblastoma.Semantic proximity Read ↗

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.Semantic proximity Read ↗

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.Semantic proximity Read ↗

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastomaSemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.Semantic proximity Read ↗

Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center.Semantic proximity Read ↗

Genetic alterations and signaling pathways in the evolution of gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.